AU2018235442A1 - Cannabinoid formulations and dosage - Google Patents
Cannabinoid formulations and dosage Download PDFInfo
- Publication number
- AU2018235442A1 AU2018235442A1 AU2018235442A AU2018235442A AU2018235442A1 AU 2018235442 A1 AU2018235442 A1 AU 2018235442A1 AU 2018235442 A AU2018235442 A AU 2018235442A AU 2018235442 A AU2018235442 A AU 2018235442A AU 2018235442 A1 AU2018235442 A1 AU 2018235442A1
- Authority
- AU
- Australia
- Prior art keywords
- cannabinoid
- week
- thc
- cbd
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 257
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 255
- 239000000203 mixture Substances 0.000 title claims description 66
- 238000009472 formulation Methods 0.000 title description 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 64
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 64
- 102000004506 Blood Proteins Human genes 0.000 claims abstract description 51
- 108010017384 Blood Proteins Proteins 0.000 claims abstract description 51
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 6
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 68
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 64
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 64
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 50
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 claims description 41
- 229960002967 nabilone Drugs 0.000 claims description 41
- 208000002193 Pain Diseases 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 28
- 208000000094 Chronic Pain Diseases 0.000 claims description 25
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 25
- 206010015037 epilepsy Diseases 0.000 claims description 25
- 230000036407 pain Effects 0.000 claims description 15
- 208000001640 Fibromyalgia Diseases 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 206010028813 Nausea Diseases 0.000 claims description 9
- 230000008693 nausea Effects 0.000 claims description 9
- 230000036528 appetite Effects 0.000 claims description 8
- 235000019789 appetite Nutrition 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 6
- 230000003902 lesion Effects 0.000 claims description 6
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims description 5
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims description 5
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims description 5
- 201000007547 Dravet syndrome Diseases 0.000 claims description 5
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims description 5
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 5
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims description 5
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 5
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 claims description 5
- 210000002161 motor neuron Anatomy 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 108010068307 Alpha-Globulins Proteins 0.000 claims description 4
- 108010087504 Beta-Globulins Proteins 0.000 claims description 4
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 claims description 4
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 claims description 4
- 206010064012 Central pain syndrome Diseases 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- YSBFLLZNALVODA-RBUKOAKNSA-N JWH-133 Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCC)=CC=C3[C@@H]21 YSBFLLZNALVODA-RBUKOAKNSA-N 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 claims description 4
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 claims description 4
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 claims description 4
- 108010074605 gamma-Globulins Proteins 0.000 claims description 4
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 claims description 3
- 101100268917 Oryctolagus cuniculus ACOX2 gene Proteins 0.000 claims 2
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 claims 2
- WVOLTBSCXRRQFR-DLBZAZTESA-M cannabidiolate Chemical compound OC1=C(C([O-])=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-M 0.000 claims 2
- 229950011318 cannabidiol Drugs 0.000 description 62
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 62
- 229940065144 cannabinoids Drugs 0.000 description 43
- 108091006905 Human Serum Albumin Proteins 0.000 description 39
- 102000008100 Human Serum Albumin Human genes 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 229960004242 dronabinol Drugs 0.000 description 33
- 239000000243 solution Substances 0.000 description 27
- 230000000202 analgesic effect Effects 0.000 description 17
- 230000004044 response Effects 0.000 description 13
- 230000003442 weekly effect Effects 0.000 description 11
- 239000007921 spray Substances 0.000 description 10
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 240000004308 marijuana Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 244000025254 Cannabis sativa Species 0.000 description 6
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000012460 protein solution Substances 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 4
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 230000007943 positive regulation of appetite Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000779 smoke Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SEEZIOZEUUMJME-VBKFSLOCSA-N Cannabigerolic acid Natural products CCCCCC1=CC(O)=C(C\C=C(\C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-VBKFSLOCSA-N 0.000 description 2
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061224 Limb discomfort Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 238000003236 bicinchoninic acid assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960003453 cannabinol Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940096431 nabilone 1 mg Drugs 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- SSNHGLKFJISNTR-DYSNNVSPSA-N (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical class OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1.C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 SSNHGLKFJISNTR-DYSNNVSPSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000003078 Generalized Epilepsy Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 244000213578 camo Species 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000003237 recreational drug Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
At least one protein-bound cannabinoid bound to a plasma protein for use as a medicament for treatment of a condition, wherein a total cannabinoid dose of the at least one protein-bound cannabinoid, administered over a time period comprising multiple administrations, is lower relative to a total cannabinoid dose of the at least one cannabinoid when administered in unbound form for achieving a same degree of therapeutic effect for treating the condition.
Description
CANNABINOID FORMULATIONS AND DOSAGE
RELATED APPLICATIONS [0001] The present application claims the benefit under 35 U.S.C. § 119(e) of US Provisional application 62/472,329 filed on March 16, 2017, whose content and disclosure are incorporated by reference in their entirety.
BACKGROUND [0002] Cannabis is a genus of plants comprising the species Cannabis sativa, C. indica, and C. ruderalis. Cannabis plants have been cultivated for a variety of uses including making fibers (hemp), medicinal use and recreational drug use. Cannabis is also commonly known as marijuana.
[0003] One of the most common ways that cannabis is used for medicinal use in many countries (also known as medical marijuana) is through smoking. Smoking cannabis is typically performed by using a pipe, by using a water-pipe (also known as a bong) which filters the smoke through water before inhalation or by rolling in paper to form marijuana cigarettes, also known colloquially as “joints.” The part of the plant typically used for smoking is the whole flower and budding leaf.
[0004] Cannabinoids are compounds active on cannabinoid receptors in humans. Cannabinoids of plant origin, also known as phyto-cannabinoids, are abundant in plants of the Cannabis genus. Two known cannabinoids which are present in relatively high concentrations in Cannabis sativa are tetrahydracannabinol-acid (THCA) or its decarboxylated product tetrahydracannabinol (THC) and cannabidiolic acid (CBDA) or its decarboxylated product cannabidiol (CBD). Psychoactive and other medical effects of many of the cannabinoids have been studied. For example, THC was found to have psychoactive (calming) effects, analgesic effects, antioxidant effects and to increase appetite. CBD was found to have neuroprotective effects and to have ameliorative effects in patients with schizophrenia and Parkinson’s disease.
[0005] Cannabinoid-containing compositions comprising at least one cannabinoid and at least one plasma protein, and methods for manufacture of such compositions have been disclosed in PCT application publication WO 2015/140736, incorporated herein by reference in its entirety.
WO 2018/167795
PCT/IL2018/050307
SUMMARY [0006] It has been found that compositions comprising cannabinoids bound to a plasma protein, upon administration to mammals, prolongs the therapeutic effect of the cannabinoids in the mammal, when compared to administration of the cannabinoids alone, in an unbound state. Accordingly, embodiments of the invention provide methods for treatment of disease comprising administering to a patient in need thereof, an amount of a composition comprising cannabinoids bound to plasma protein, in which the daily dosage administered is a reduced amount relative to the daily dosage of the cannabinoids not bound to plasma protein, in order to achieve the same therapeutic effect.
[0007] Additional embodiments provide methods for treatment of disease comprising administering to a patient in need thereof, an amount of a composition comprising cannabinoids bound to plasma protein in which the composition is administered less frequently than the administration of the cannabinoid alone, without being bound the plasma protein prior to administration, in order to achieve the same or better therapeutic effect as a same or higher dose of unbound cannabinoid.
[0008] In accordance with an embodiment of the disclosure, a composition comprising cannabinoids in a plasma protein-bound form are administered at intervals of two-fold to threefold duration compared to a same dose of cannabinoids in non-protein-bound form, such that, by way of example, where non-plasma protein-bound cannabinoid is typically treated with twice or thrice daily administration for a given condition, a once-daily administration of the same amount of cannabinoid in plasma protein-bound form provides a same or better therapeutic effect. As a result of the increased time interval between administrations, the total amount of cannabinoid administered in accordance with an embodiment of the disclosure, in the form of being bound to a protein, over a time period comprising multiple administrations is reduced to between one-half and one-third compared to unbound cannabinoid, while achieving a same or better therapeutic effect. Alternatively or in combination, the amount of cannabinoid per administration for the cannabinoid in protein-bound form is reduced, optionally to account for the longer duration of effectiveness or improved potency. Optionally, the amount of cannabinoid administered in the protein-bound form at each administration for achieving a same or better therapeutic effect is between 0.7-fold and 0.5-fold compared to the amount of unbound cannabinoid.
[0009] In an embodiment of the disclosure, for administration of a protein-bound cannabinoid, a prolonged, up to threefold, time interval for administration (compared to unbound cannabinoid) is combined with a reduced amount, up to half, of cannabinoid per administration (compared to
WO 2018/167795
PCT/IL2018/050307 unbound cannabinoid). A result of such a combination, when administered in the form of a protein-bound cannabinoid in accordance with an embodiment of the disclosure, the total amount of cannabinoid administered over a time period comprising multiple administrations is between about one-third and about one-sixth of the total amount of unbound cannabinoid administered over the same multiple-dose time period for achieving a same or better therapeutic effect.
[0010] In an embodiment of the disclosure, the plasma protein is non-covalently bound to the at least one cannabinoid, resulting in the formation of a protein-cannabinoid complex. Optionally, the non-covalent binding is characterized by non-specific lipophilic and polar interactions, by way of example with hydrophobic protein pockets in the plasma protein.
[0011] According to an embodiment of the invention, the composition comprises one of or a combination of more than one of albumin, lipoprotein, glycoprotein, α, β, and γ globulin and diluted blood plasma.
[0012] According to an embodiment of the invention, the composition comprises a cannabinoid selected from the group consisting of A9-THC, A8-THC, tetrahydrocannabinoic acid (THCA), CBD, cannabidiolic acid (CBDA), cannabinol (CBN), cannabigerol (CBG), tetrahydrocannabivarin (THCV), cannabigerolic acid (CBGA) and cannabichromene (CBC). According to an embodiment of the invention, the composition comprises a mixture of cannabinoids. According to an embodiment of the invention, the cannabinoid is a synthetic cannabinoid. The synthetic cannabinoid may be dronabinol, nabilone, HU-210, WIN 55,2122 or JWH-133.
[0013] According to an embodiment of the invention, the cannabinoid is THC. According to an embodiment of the invention, the plasma protein is an albumin. The albumin may comprise human serum albumin, bovine serum albumin or egg albumin (OVA).
[0014] According to an embodiment of the invention, the method of treatment relates to treating a disease associated with: conditions of pain relating to chemotherapy; conditions of pain and wasting syndrome in connection with AIDS; nausea and vomiting, nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia; personality disorder; psychosis; depression; neurodegenerative disease; hypoxia, comprising stroke or trauma; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsy; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, Alzheimer's disease; arthritis; glaucoma; migraine; PTSD; Crohn’s disease; tremor, Parkinsonian tremor;
WO 2018/167795
PCT/IL2018/050307 attention deficit disorder; attention deficit hyperactivity disorder; irritable bowel syndrome or dysmenorrhoea. Treating a disease as used herein refers to reducing or eliminating the disease or alternatively reducing or eliminating one or more symptoms associated with or caused by the disease.
[0015] This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
BRIEF DESCRIPTION OF FIGURES [0016] Non-limiting examples of embodiments are described below with reference to figures attached hereto that are listed following this paragraph. Identical structures, elements or parts that appear in more than one figure are generally labeled with a same numeral in all the figures in which they appear, and a numeral labeling an icon representing a given feature in a figure may be used to reference the given feature. Dimensions of components and features shown in the figures are chosen for convenience and clarity of presentation and are not necessarily shown to scale.
[0017] Fig. 1 depicts a line graph showing response latency of mice (in seconds) tested using a hot plate test at various time points administered one of: an ethanolic composition comprising cannabinoids without plasma protein (Eth-THC), a composition comprising cannabinoids bound to plasma protein (CannTrap), or a negative control (Control) comprising ethanol without cannabinoid;
[0018] Fig. 2 depicts a line graph showing response latency of mice (in seconds) tested using a hot plate test at various time points administered one of: an ethanolic composition comprising cannabinoids (Eth-THC) without plasma protein and a mixed composition (Eth-THC + protein) comprising the Eth-THC composition mixed with a plasma protein solution 5 minutes prior to administration; and [0019] Fig. 3 depicts a graph response latency of mice (in seconds) tested using a hot plate test at various time points administrated one of: a solution comprising plasma protein and unbound cannabinoids (Eth-THC + protein), a composition comprising cannabinoids bound to plasma protein (CannTrap).
WO 2018/167795
PCT/IL2018/050307
DETAILED DESCRIPTION [0020] Example la: Preparation of an ethanolic solution comprising cannabinoids [0021] Smoke of cannabis plant material high in THC was formed by burning, and the smoke was streamed through anhydrous ethanol. The solution was concentrated by evaporation of ethanol up to a total cannabinoid concentration of between 1.5 milligram (mg) per milliliter (ml) and 5 mg/ml, the concentration being determined using quantitative HPLC (high-pressure liquid chromatography) -based analysis.
[0022] Example lb: Preparation of “CannTrap”, a composition comprising cannabinoids bound to plasma protein [0023] 100 microliters (μΐ) of the concentrated ethanolic solution prepared in accordance with
Example la above was slowly added to 500μ1 of a 2 mg/ml solution of rice recombinant human serum albumin (HSA), a plasma protein. The cannabinoid-protein solutions were formed using ethanol and water in a 1:5 ratio. The cannabinoid-protein solutions were incubated under ventilated conditions at 30°C for 16 hours to allow slow ethanol evaporation from the solution to favor binding of cannabinoids with the HSA. After incubation, the cannabinoid-protein solutions were loaded onto a 0.5 ml Amicon 0.3 kilodalton (kDa) filter (Millipore). HSA molecules, which exceed the 0.3 kDa cutoff of the filter, as well as any compounds bound to the HSAs, would be unable to pass the filter, while compounds smaller than the 0.3 kDa cutoff, including free cannabinoids and fatty acids not bound to HSAs, as well as any residual ethanol, would pass through the filter. The complex was washed twice with 500μ1 of water. Protein, which included HSA bound with cannabinoids, was eluted from the amicon filter, resulting in a purified composition that is enriched in HSA-bound cannabinoid. This resulting composition is referred to herein as a “CannTrap” composition.
[0024] Cannabinoids and HSA concentrations in the CannTrap composition were determined using HPLC-based quantification and a bicinchoninic acid assay (BCA), respectively. The final concentration of the cannabinoids in complex with protein in the CannTrap composition depends on the final elution volume and can be up to 70 mg/ml or higher for HSA and up to 3 mg/ml or higher for cannabinoids, and the relative amount of cannabinoid to HSA can be between 20 micrograms (pg) and 100 pg of cannabinoid to 1 mg of HSA.
[0025] The relative quantity of various cannabinoids in each of the Eth-THC solution and the CannTrap composition, expressed as a percentage of total cannabinoid composition, is listed in Table 1 below:
WO 2018/167795
PCT/IL2018/050307 [0026] Table 1:
Cannabinoid | Eth-THC solution (% total cannabinoid) | CannTrap composition (% total cannabinoid) |
CBDA | 0.5 | 1.2 |
CBGA | 0.4 | 0.4 |
CBG | 3.5 | 8.6 |
CBD | - | 0.0 |
CBN | 6.9 | 5.3 |
THCA | 2.7 | 1.7 |
THC | 83.0 | 80.9 |
CBC | 3.0 | 1.8 |
[0027] Example 2a: Testing analgesic effect of CannTrap composition [0028] The hot plate pain test is a well-established murine model to test the analgesic effect of tested compounds. A head-to-head comparison of analgesic effect as assayed by the hot plate pain test was made between compositions comprising cannabinoids extracted from cannabis smoke in ethanol without plasma protein (the Eth-THC solution produced in accordance with Example la) with a composition comprising HSA-bound cannabinoinds (the CannTrap composition produced in according with Example lb). Male C57BL/6J01aHsd mice, aged 9-10 weeks at study initiation, were divided into 3 groups with 6-7 mice per group.
[0029] The results of the comparison are shown in Fig. 1. A first group was treated with the EthTHC solution (indicated in Fig. 1 as “Eth-THC”, having square plot markers), a second group was treated with the CannTrap composition comprising HSA-bound cannabinoid (indicated in Fig. 1 as “CannTrap”, having diamond plot markers), and a third, control, group was administered ethanol only, without any cannabinoid (indicated in the figure as “Control”, having triangular plot markers). The target THC dosage per injection was 5 mg THC / kilograms (kg) body weight.
WO 2018/167795
PCT/IL2018/050307 [0030] The injected mice were then tested by placing each mouse on an electronically controlled hot plate (hotplate analgesia meter, Columbus Instruments, Columbus, Ohio, USA) heated to 51 °C at 25, 60, 100, 140, 180, 220 and 260 minutes after injection, to test response latency in seconds. Latency was defined as time between the animal being placed on the hot plate surface and the animal showing a first sign of discomfort (licking its paw, shaking or jumping off to avoid thermal pain.) In attempt to reduce mistake of the identification of the first sign of discomfort, the first sign of discomfort of the front leg was disregarded, and times for first sign of hind-leg discomfort and first hind-leg licking were recorded. Results are shown as the mean time of the first sign of hind-leg discomfort and hind-leg licking.
[0031] The results show that treatment with 5 mg/kg THC in the form of an ethanolic cannabinoid solution (Eth-THC) provided analgesic effect, demonstrated in the form of longer response latency for the hot-plate test compared to response latency for control animals treated with ethanol vehicle was about 20 seconds. Treatment with the Eth-THC solution resulted in response latency increasing to a maximum of over 30 seconds (at 25 minutes post-injection), representing a 1.5-fold increase over control. The response latency decreased after 25 minutes and returned to baseline levels by 100 minutes post-treatment, thus showing that injection of ethanolic cannabinoid provided analgesic effect for a duration of less than 100 minutes.
[0032] By contrast, a 5 mg/kg dose of THC in the form of HSA-bound cannabinoid (CannTrap) provided significantly stronger analgesic effect for a longer duration. Treatment with the CannTrap composition resulted in response latency of about 35 seconds at 25 minutes postinjection, equivalent to ethanolic cannabinoid (Eth-THC). However, the response latency in the group treated the CannTrap composition continued to increase thereafter, increasing to a maximum of over 50 seconds at 100 minutes post-injection, representing a 2.5-fold increase in response latency over control. Therefore, HSA-bound cannabinoid was found to be about 1.7fold (2.5 divided by 1.5) more potent than ethanolic cannabinoid for inducing analgesia. As such, administering the CannTrap composition at a reduced dose to administer about 3 mg/kg THC (0.58-fold dose compared to 5 mg/kg THC) would be expected to result in a similar maximum response latency as administering 5 mg/kg of unbound THC.
[0033] Moreover, the duration of the analgesic effect of HSA-bound cannabinoid treatment was longer compared to ethanolic cannabinoid, with the response latency approaching baseline at 260 minutes post-injection. Therefore, compared to ethanolic cannabinoid, which had already returned to baseline levels by 100 minutes post-injection, HSA-bound cannabinoid was found to induce analgesia for a duration of at least 2.6-fold longer than ethanolic cannabinoid.
WO 2018/167795
PCT/IL2018/050307 [0034] Example 2b: Analgesic effect of ethanolic cannabinoid solution compared to a mixture of HSA and cannabinoid not bound to the HSA [0035] Reference is made to Figs. 2 and 3. Using the same hot plate assay, the analgesic effect of a solution comprising HSA and cannabinoid, in which the cannabinoids had not had optimal conditions to bind to HSA, was tested. The unbound mix solution (Eth-THC + Protein) was prepared by combining the ethanolic cannabinoid (Eth-THC) prepared in accordance with Example la with an aqueous solution comprising HSA immediately prior to intraperitoneal injection. The solution was prepared so that the final ethanol concentration of the unbound mixture solution was less than 5% and the THC concentration was 0.5 mg THC / ml. The unbound mix solution was injected within 5 minutes of preparation. Given the relatively low ethanol concentration of the Eth-THC + Protein solution and the shortness of time between preparation and administration, the presence of HSA-bound cannabinoid was expected to be negligible. The analgesic effect of injecting the unbound mix solution (Eth-THC + Protein) was compared to the analgesic effects of ethanolic cannabinoid (Eth-THC) and HSA-bound cannabinoid (CannTrap). Each mouse receiving a THC-comprising composition, (Eth-THC, Eth-THC + Protein, or CannTrap) had the composition administered at a dose of 5 mg THC / kg body weight.
[0036] A comparison of the analgesic effect the Eth-THC solution and the Eth-THC + Protein solution is shown in Fig. 2. It is found that the analgesic effect of the unbound mix solution (EthTHC + Protein, shown in Fig. 2 with x-shaped plot markers) is substantially the same as the ethanolic cannabinoid solution (Eth-THC), shown in Fig. 2 with triangular plot markers), confirming that merely the presence of HSA in a same solution as cannabinoids does not confer the advantageous properties of HSA-bound cannabinoids. The time course of the analgesic effect of unbound mix solution was essentially the same as that of ethanolic cannabinoids, and the analgesic effect had dissipated by 100 minutes post-injection in both treatments. By contrast, as shown in Fig. 3, HSA-bound cannabinoid (CannTrap, shown with square plot markers) maintained analgesic effect until 200 minutes post-injection for, twice as long as the unbound mix solution (Eth-THC + Protein, shown with diamond plot markers).
[0037] These results indicate that a prolonged effect of the same dosage of cannabinoid may be achieved when cannabinoids are administered already bound to a plasma protein. The potential advantages are many and include the following advantages: 1. Lower cannabinoid dosages may be administered, in compositions comprising plasma protein-bound cannabinoids, to patients in need thereof to provide similar effects as higher cannabinoid dosage using non-plasma-protein
WO 2018/167795
PCT/IL2018/050307 bound composition. 2. Side effects associated with administering cannabinoids may be decreased by using compositions comprising cannabinoids bound to plasma protein. 3. Accumulation of cannabinoid in tissue of patients may be lowered by using a lower daily dosage of plasma proteinbound cannabinoid 4. Frequency of administration may be altered to provide fewer administrations of compositions comprising plasma protein-bound cannabinoids to a patient in need thereof per day (or per other period of time) than required when administering cannabinoids without plasma proteins.
[0038] Example 3: Clinical uses of composition comprising cannabinoid and plasma protein [0039] CannTrap compositions comprising cannabinoid bound to protein (such as HSA) are be used in a clinical setting using alternate dosing schedules relative to those used for cannabinoids administered without plasma proteins. In accordance with an embodiment of the disclosure, compositions comprising cannabinoids in a plasma protein-bound (CannTrap) form are administered less frequently, by way of example with a dose interval that is two-fold to threefold longer compared to same dose of cannabinoids in non-protein-bound form. As such, where non-plasma protein-bound cannabinoid is recommended for twice or thrice daily administration, a same dose of plasma protein-bound cannabinoid provides a same or better effectiveness when administered once a day. Alternatively or in combination, the amount of cannabinoid per administration may be reduced, optionally to account for the longer duration of effectiveness and/or improved potency of the protein-bound CannTrap cannabinoid. Table 2 and further examples below details exemplary methods of treatment according to dosing schedules that may be followed using CannTrap compositions comprising plasma protein-bound cannabinoid.
WO 2018/167795
PCT/IL2018/050307 [0040] Table 2:
Indication | Cannabinoid used | Known dosage of cannabinoid | Exemplary cannabinoid dosage for composition comprising plasma protein-bound cannabinoid |
appetite stimulation | Δ-9-THC (dronabinol) | 5 mg/day (twice daily) | 1 -5 mg/day once daily |
appetite stimulation | Δ-9-THC (dronabinol) | 2.5 mg/day (once daily) | 0.2-1.25 mg/day once daily |
emesis (nausea and vomiting) | Δ-9-THC (dronabinol) | 2.5mg - 40 mg/day (four times daily) | 2.5 - 40 mg/day twice daily |
emesis | nabilone | 1 mg - 2 mg/day (twice daily) | 1-2 mg/day once daily |
pain/ fibromyalgia | nabilone | Img - 2 mg/day (twice daily); 0.5 mg to 1 mg before sleep for improved sleep | Up to 1 mg/day once daily |
chronic upper motor neuron syndrome/ central pain | nabilone | 1 mg/day (once daily) | 0.5 mg/day once daily |
Epilepsy | CBD | 200 mg/day | 100 mg/day |
Dravet syndrome | CBD | 20 mg/kg/day | 10 mg/kg/day |
Lennox-Gastaut Syndrome | CBD | 20 mg/kg/day | 10 mg/kg/day |
pain (multiple sclerosis related) | combination of CBD and THC (nabiximols) | 100 μΐ/spray comprising 27mg/ml THC (2.7 mg THC per spray) and 25 mg/ml CBD (2.5 mg CBD per spray), median of 5 sprays per day, up to 12 sprays per day. | 100 μΐ/spray comprising 27mg/ml THC and 25 mg/ml CBD, median of 2.5 sprays per day, up to 6 sprays per day. |
[0041] Given its improved potency and/or duration of action, a CannTrap protein-bound cannabinoid in accordance with an embodiment of the disclosure is expected to have a same or better therapeutic effect for stimulating appetite compared to unbound cannabinoid when administered with a total administered amount of cannabinoid over multiple doses that is
WO 2018/167795
PCT/IL2018/050307 between about one-sixth and one-half of the total administered amount of the same cannabinoid in unbound form. As such, the following further examples are also provided.
[0042] Example 3A - Protein-bound THC for appetite stimulation [0043] A typical dosing schedule for stimulating appetite, in subjects suffering from reduced appetite associated with, by way of example, chemotherapy or AIDS, with orally administered dronabinol (unbound Δ-9-THC) can be as low as 2.5 mg/day, which is equivalent to a weekly dose of about 17.5 mg/week. By way of example, a CannTrap HSA-bound Δ-9-THC in accordance with an embodiment of the disclosure, administered orally at a total dosage of between about 3 mg/week Δ-9-THC and about 9 mg/week Δ-9-THC, is as effective in stimulating appetite as 17.5 mg/week of dronabinol (unbound Δ-9-THC).
[0044] Example 3B - Protein-bound THC for treating nausea [0045] A typical dosing schedule for treating nausea (for example associated with chemotherapy) with orally administered Δ-9-THC can be as low as 2.5 mg/day four times a day, which is equivalent to a weekly dose of about 70 mg/week. By way of example, a CannTrap HSA-bound Δ-9-THC administered orally at a total dosage of between about 12 mg/week Δ-9THC and about 35 mg/week Δ-9-THC is as effective in treating nausea as 70 mg/week of unbound Δ-9-THC.
[0046] Example 3C - Protein-bound nabilone for treating nausea [0047] A typical dosing schedule for treating nausea (for example associated with chemotherapy) with orally administered nabilone can be as low as 1 mg/day twice a day, which is equivalent to a weekly dose of 14 mg/week. By way of example, a CannTrap HSA-bound nabilone administered orally at a total dosage of between about 2 mg/week nabilone and about 7 mg/week nabilone is as effective in treating nausea as 14 mg/week of unbound nabilone.
[0048] Example 3D - Protein-bound nabilone for treating pain associated with fibromyalgia [0049] A typical dosing schedule for treating chronic pain associated with fibromyalgia with orally administered nabilone can be as low as 1 mg/day twice a day, which is equivalent to a weekly dose of 14 mg/week. By way of example, a CannTrap HSA-bound nabilone administered orally at a total dosage of between about 2 mg/week nabilone and about 7 mg/week nabilone is as effective in treating fibromyalgia-associated pain as 14 mg/week of unbound nabilone.
[0050] Example 3E - Protein-bound nabilone for treating chronic pain [0051] Another typical dosing schedule for treating chronic pain (by way of example associated with fibromyalgia, upper motor neuron syndrome and/or central pain syndrome) with orally administered nabilone can be as low as 0.5 mg before bedtime, which is equivalent to a weekly
WO 2018/167795
PCT/IL2018/050307 dose of 3.5 mg/week. By way of example, a CannTrap HSA-bound nabilone administered orally at a total dosage of between about 0.6 mg/week nabilone and about 1.75 mg/week nabilone is as effective in treating fibromyalgia-associated pain as 3.5 mg/week of unbound nabilone.
[0052] Example 3F - Protein-bound THC for treating chronic pain [0053] Another typical dosing schedule for treating chronic pain (by way of example associated with cancer) with orally administered THC can be as low as 5 mg daily, which is equivalent to a weekly dose of 35 mg/week. By way of example, a CannTrap HSA-bound THC administered orally at a total dosage of between about 6 mg/week THC and about 17.5 mg/week THC is as effective in treating chronic pain as 35 mg/week of unbound THC.
[0054] Example 3F - Protein-bound CBD for treating epilepsy [0055] A typical dosing schedule for treating epilepsy with orally administered CBD can be about 200 mg daily, which is equivalent to a weekly dose of 1400 mg/week. By way of example, a CannTrap HSA-bound CBD administered orally at a total dosage of between about 233 mg/week CBD and about 700 mg/week CBD is as effective in treating epilepsy as 1400 mg/week of unbound CBD.
[0056] Example 3G - Protein-bound CBD for treating epilepsy [0057] A typical dosing schedule for treating epilepsy with orally administered CBD can be as low as 5 mg/kg daily, which is equivalent to a weekly dose of 35 mg/kg/week. By way of example, a CannTrap HSA-bound CBD administered orally at a total dosage of between about 5.5 mg/kg/week CBD and about 17.5 mg/kg/week CBD is as effective in treating epilepsy as 35 mg/kg/week of unbound CBD.
[0058] Example 3H - Protein-bound CBD for treating epilepsy [0059] A typical dosing schedule for treating Dravet Sydrome (also known as severe myoclonic epilepsy of infancy) or epilepsy in patients of Lennox-Gastaut Syndrome with orally administered CBD can be about 20 mg/kg daily, which is equivalent to a weekly dose of 140 mg/kg/week. By way of example, a CannTrap HSA-bound CBD administered orally at a total dosage of between about 23 mg/week CBD and about 70 mg/week CBD is as effective in treating epilepsy as 350 mg/week of unbound CBD.
[0060] Example 31 - Protein-bound CBD and THC for treating epilepsy [0061] A typical dosing schedule for chronic pain (by way of example associated with nerve lesion, rheumatoid arthritis, cancer, and multiple sclerosis) with a combination of THC and CBD via oromucosal spray be as low as about 2.7 mg THC and about 2.5 mg CBD daily, which is equivalent to a weekly dose of about 19 mg/week THC with about 17.5 mg/week CBD. By way
WO 2018/167795
PCT/IL2018/050307 of example, a CannTrap HSA-bound CBD administered orally at a total dosage of between about 3.2 mg/week THC with about 2.9 mg/week CBD and about 9.5 mg/week THC with about 8.7 mg/week CBD is as effective in treating epilepsy as about 19 mg/week THC with about 17.5 mg/week CBD.
[0062] Example 3J - Protein-bound CBD and THC for treating chronic pain [0063] A typical dosing schedule for chronic pain (by way of example associated with nerve lesion, rheumatoid arthritis, cancer, and multiple sclerosis) with a combination of THC and CBD via oromucosal spray be as low as about 2.7 mg THC and about 2.5 mg CBD daily, which is equivalent to a weekly dose of about 19 mg/week THC with about 17.5 mg/week CBD. By way of example, a CannTrap HSA-bound CBD administered orally at a total dosage of between about 3.2 mg/week THC with about 2.9 mg/week CBD and about 9.5 mg/week THC with about 8.7 mg/week CBD is as effective in treating epilepsy as about 19 mg/week THC with about 17.5 mg/week CBD.
[0064] According to an embodiment of the invention, appetite stimulation may be treated in patients suffering from AIDS, including AIDS related weight loss. According to an embodiment of the invention, emesis may be treated in a patient receiving chemotherapy and suffering from chemotherapy induced emesis. According to an embodiment of the invention, pain may be treated in patients suffering from neuropathic pain, chronic pain, cancer, multiple sclerosis or post-operative pain.
[0065] The pharmaceutical compositions according to an embodiment of the invention are conveniently presented in unit dosage form and are prepared by any of the methods well known in the art of pharmacy. In an embodiment of the invention, the unit dosage form is in the form of a tablet, capsule, lozenge, wafer, patch, ampoule, vial, metered-dose inhaler (oral or nasal route) or pre-filled syringe.
[0066] In an embodiment of the disclosure, the at least one protein-bound cannabinoid of the present disclosure is administered in the form of a pharmaceutical composition comprising at least one protein-bound cannabinoid as an active component together with a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition is optionally administered through oral administration, parenteral administration, or inhalation.
[0067] According to an embodiment of the invention, more than 90% of the cannabinoids in the composition is bound to plasma protein. According to an embodiment of the invention, the composition is substantially free from cannabinoid not bound to the plasma protein.
WO 2018/167795
PCT/IL2018/050307 [0068] For oral administration a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, and the like. Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the components of this invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof. In an embodiment of the disclosure, plasma-protein-bound cannabinoid may be administered orally together with a protease inhibitor and/or a buffering agent. For intranasal administration, a pharmaceutical composition can take the form of solutions, suspensions, powders and the like.
[0069] The compositions according to embodiments of this invention may also be administered in a controlled release formulation such as a slow release or a fast release formulation. Such controlled release dosage composition may be prepared using methods well known to those skilled in the art.
[0070] For purposes of parenteral administration, aqueous solutions may be prepared. Such aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes.
[0071] Pharmaceutical compositions according to embodiments of the invention may contain an active amount of 0.1%-95% of the protein-bound cannabinoid(s) (based on total cannabinoid weight) preferably l%-70%.
[0072] In an embodiment of the invention, the daily dosage of the protein-bound cannabinoid, is between 0.1 pg and 1500 mg. Some embodiments of the invention relate to treatments as monotherapy, in which a protein-bound cannabinoid is a sole active pharmaceutical agent used to treat a disease. Some embodiments of the invention relate to combination therapies in which a protein-bound cannabinoid is used in combination with another active pharmaceutical agent to treat a disease. “In combination with” refers to both drugs being substantially effective in the
WO 2018/167795
PCT/IL2018/050307 body at a same time. Both drugs can be administered substantially at the same time, or both drugs can be administered at different times but have effect on the body at the same time.
[0073] There is therefore provided in accordance with the disclosure at least one protein-bound cannabinoid bound to a plasma protein for use as a medicament for treatment of a condition, wherein a total cannabinoid dose of the at least one protein-bound cannabinoid, administered over a time period comprising multiple administrations, is lower relative to a total cannabinoid dose of the at least one cannabinoid when administered in unbound form for achieving a same degree of therapeutic effect for treating the condition. There is also provided in accordance with the disclosure a method for treating a subject having or suffering from a condition and in need thereof, the method comprising administering to the subject an therapeutically effective amount of a composition comprising at least one cannabinoid bound to a plasma protein or portion thereof, in which a total cannabinoid dose of the at least one cannabinoid, administered over a time period comprising multiple administrations, is lower relative to a total cannabinoid dose of the at least one cannabinoid in unbound form for achieving a same degree of therapeutic effect.
[0074] In an embodiment of the disclosure, time intervals between administrations of the at least one plasma protein-bound cannabinoid is between about two-fold and about three-fold longer in duration compared to a dosing schedule for achieving the same degree of therapeutic effect with administration of the at least one cannabinoid in unbound form.
[0075] In an embodiment of the disclosure, the amount of cannabinoid administered at each of the multiple administrations of the at least one plasma protein-bound cannabinoid is between about 0.7-fold and about 0.5-fold lower compared of the amount of the at least one cannabinoid administered in unbound form.
[0076] In an embodiment of the disclosure, the total amount of the at least one protein-bound cannabinoid administered over the multiple administrations is between one-sixth and one-half relative to the total administered dose of the at least one cannabinoid in unbound form for achieving the same degree of therapeutic effect.
[0077] In an embodiment of the disclosure, the at least one protein-bound cannabinoid is one or a combination of two or more of the group consisting of: THCA, A9-THC, A8-THC, CBDA, CBD, CBN, CBG, THCV, CBGA, CBC, HU-210, WIN 55,212-2 and JWH-133, and nabilone.
WO 2018/167795
PCT/IL2018/050307 [0078] In an embodiment of the disclosure, the plasma protein or portion thereof is selected from the group consisting of: an albumin, a lipoprotein, a glycoprotein, and α, β, and γ globulins, and mixtures of one or more thereof.
[0079] Optionally, the condition is reduced appetite, the at least one cannabinoid comprises Δ9THC, and the at least one cannabinoid is administered at a dose of between about 3 mg/week Δ-9-THC and about 9 mg/week Δ-9 THC.
[0080] Optionally, the condition is nausea, the at least one cannabinoid comprises A-9THC, and the at least one cannabinoid is administered at a dose of between about 12 mg/week Δ-9-THC and about 35 mg/week Δ-9 THC.
[0081] Optionally, the condition is pain associated with fibromyalgia, the at least one cannabinoid comprises nabilone, and the at least one cannabinoid is administered at a dose of between about 2 mg/week nabilone and about 7 mg/week nabilone.
[0082] Optionally, the condition is chronic pain, the at least one cannabinoid comprises nabilone, and the at least one cannabinoid is administered at a dose of between about 0.6 mg/week nabilone and about 1.75 mg/week nabilone. Optionally, the chronic pain is associated with one or more of fibromyalgia, upper motor neuron syndrome, and central pain syndrome.
[0083] Optionally, the condition is chronic pain associated with cancer, the at least one cannabinoid comprises THC, and the at least one cannabinoid is administered at a dose of between about 6 mg/week THC and about 17.5 mg/week THC.
[0084] Optionally, the condition is epilepsy, the at least one cannabinoid comprises CBD, and the at least one cannabinoid is administered at a dose of between about 233 mg/week CBD and about 700 mg/week CBD.
[0085] Optionally, the condition is epilepsy, the at least one cannabinoid comprises CBD, and the at least one cannabinoid is administered at a dose of between about 5.5 mg/kg/week CBD and about 17.5 mg/kg/week CBD.
[0086] Optionally, the condition is epilepsy associated with Dravet Syndrome or LennoxGastaut Syndrome, the at least one cannabinoid comprises CBD, and the at least one cannabinoid is administered at a dose of between about 23 mg/kg/week CBD and about 70 mg/kg/week CBD.
WO 2018/167795
PCT/IL2018/050307 [0087] Optionally, the condition is epilepsy, the at least one cannabinoid comprises CBD and THC, and the at least one cannabinoid is administered at a dose of between about 3.2 mg/week THC with about 2.9 mg/week CBD and about 9.5 mg/week THC with about 8.7 mg/week CBD.
[0088] Optionally, the condition is chronic pain, the at least one cannabinoid comprises CBD and THC, and the at least one cannabinoid is administered at a dose of between about 3.2 mg/week THC with about 2.9 mg/week CBD and about 9.5 mg/week THC with about 8.7 mg/week CBD. The chronic pain optionally is associated with one or more of a nerve lesion, rheumatoid arthritis, a cancer, and multiple sclerosis.
[0089] In the description and claims of the present application, each of the verbs, “comprise,” “include” and “have,” and conjugates thereof, are used to indicate that the object or objects of the verb are not necessarily a complete listing of components, elements or parts of the subject or subjects of the verb.
[0090] Descriptions of embodiments of the invention in the present application are provided by way of example and are not intended to limit the scope of the invention. The described embodiments comprise different features, not all of which are required in all embodiments of the invention. Some embodiments utilize only some of the features or possible combinations of the features. Variations of embodiments of the invention that are described, and embodiments of the invention comprising different combinations of features noted in the described embodiments, will occur to persons of the art. The scope of the invention is limited only by the claims.
Claims (36)
1. At least one protein-bound cannabinoid bound to a plasma protein for use as a medicament for treatment of a condition, wherein a total cannabinoid dose of the at least one protein-bound cannabinoid, administered over a time period comprising multiple administrations, is lower relative to a total cannabinoid dose of the at least one cannabinoid when administered in unbound form for achieving a same degree of therapeutic effect for treating the condition.
2. The at least one protein-bound cannabinoid according to claim 1, wherein time intervals between administrations of the at least one plasma protein-bound cannabinoid is between about two-fold and about three-fold longer in duration compared to a dosing schedule for achieving the same degree of therapeutic effect with administration of the at least one cannabinoid in unbound form.
3. The at least one protein-bound cannabinoid according to claim 1, wherein the amount of cannabinoid administered at each of the multiple administrations of the at least one plasma protein-bound cannabinoid is between about 0.7-fold and about 0.5-fold lower compared of the amount of the at least one cannabinoid administered in unbound form.
4. The at least one protein-bound cannabinoid according to claim 1, wherein the total amount of the at least one protein-bound cannabinoid administered over the multiple administrations is between one-sixth and one-half relative to the total administered dose of the at least one cannabinoid in unbound form for achieving the same degree of therapeutic effect.
5. The at least one protein-bound cannabinoid according to claim 1, wherein the at least one protein-bound cannabinoid is one or a combination of two or more of the group consisting of: THCA, A9-THC, A8-THC, CBDA, CBD, CBN, CBG, THCV, CBGA, CBC, HU-210, WIN 55,212-2 and JWH-133, and nabilone.
6. The at least one protein-bound cannabinoid according to claim 1, wherein the plasma protein or portion thereof is selected from the group consisting of: an albumin, a lipoprotein, a glycoprotein, and α, β, and γ globulins, and mixtures of one or more thereof.
WO 2018/167795
PCT/IL2018/050307
7. The at least one protein-bound cannabinoid according to claim 1, wherein the condition is reduced appetite, the at least one cannabinoid comprises A-9THC, and the at least one cannabinoid is administered at a dose of between about 3 mg/week Δ9-THC and about 9 mg/week Δ-9 THC.
8. The at least one protein-bound cannabinoid according to claim 1, wherein the condition is nausea, the at least one cannabinoid comprises A-9THC, and the at least one cannabinoid is administered at a dose of between about 12 mg/week Δ-9-THC and about 35 mg/week Δ-9 THC.
9. The at least one protein-bound cannabinoid according to claim 1, wherein the condition is pain associated with fibromyalgia, the at least one cannabinoid comprises nabilone, and the at least one cannabinoid is administered at a dose of between about 2 mg/week nabilone and about 7 mg/week nabilone.
10. The at least one protein-bound cannabinoid according to claim 1, wherein the condition is chronic pain, the at least one cannabinoid comprises nabilone, and the at least one cannabinoid is administered at a dose of between about 0.6 mg/week nabilone and about 1.75 mg/week nabilone.
11. The at least one protein-bound cannabinoid according to claim 10, wherein the chronic pain is associated with one or more of fibromyalgia, upper motor neuron syndrome, and central pain syndrome.
12. The at least one protein-bound cannabinoid according to claim 1, wherein the condition is chronic pain associated with cancer, the at least one cannabinoid comprises THC, and the at least one cannabinoid is administered at a dose of between about 6 mg/week THC and about 17.5 mg/week THC.
13. The at least one protein-bound cannabinoid according to claim 1, wherein the condition is epilepsy, the at least one cannabinoid comprises CBD, and the at least one cannabinoid is administered at a dose of between about 233 mg/week CBD and about 700 mg/week CBD.
14. The at least one protein-bound cannabinoid according to claim 1, wherein the condition is epilepsy, the at least one cannabinoid comprises CBD, and the at least one cannabinoid is administered at a dose of between about 5.5 mg/kg/week CBD and about 17.5 mg/kg/week CBD.
WO 2018/167795
PCT/IL2018/050307
15. The at least one protein-bound cannabinoid according to claim 1, wherein the condition is epilepsy associated with Dravet Syndrome or Lennox-Gastaut Syndrome, the at least one cannabinoid comprises CBD, and the at least one cannabinoid is administered at a dose of between about 23 mg/kg/week CBD and about 70 mg/kg/week CBD.
16. The at least one protein-bound cannabinoid according to claim 1, wherein the condition is epilepsy, the at least one cannabinoid comprises CBD and THC, and the at least one cannabinoid is administered at a dose of between about 3.2 mg/week THC with about 2.9 mg/week CBD and about 9.5 mg/week THC with about 8.7 mg/week CBD.
17. The at least one protein-bound cannabinoid according to claim 1, wherein the condition is chronic pain, the at least one cannabinoid comprises CBD and THC, and the at least one cannabinoid is administered at a dose of between about 3.2 mg/week THC with about 2.9 mg/week CBD and about 9.5 mg/week THC with about 8.7 mg/week CBD.
18. The at least one protein-bound cannabinoid according the claim 17, wherein the chronic pain is associated with one or more of a nerve lesion, rheumatoid arthritis, a cancer, and multiple sclerosis.
19. A method for treating a subject in need thereof, the method comprising administering to the subject an therapeutically effective amount of a composition comprising at least one cannabinoid bound to a plasma protein or portion thereof, in which a total cannabinoid dose of the at least one cannabinoid, administered over a time period comprising multiple administrations, is lower relative to a total cannabinoid dose of the at least one cannabinoid in unbound form for achieving a same degree of therapeutic effect.
20. The method according to claim 19, wherein time intervals between administrations of the at least one plasma protein-bound cannabinoid is between about two-fold and about three-fold longer in duration compared to a dosing schedule for achieving the same degree of therapeutic effect with administration of the at least one cannabinoid in unbound form.
WO 2018/167795
PCT/IL2018/050307
21. The method according to claim 19, wherein the amount of cannabinoid administered at each of the multiple administrations of the at least one plasma protein-bound cannabinoid is between about 0.7-fold and about 0.5-fold lower compared of the amount of the at least one cannabinoid administered in unbound form.
22. The method according to claim 19, wherein the total amount of the at least one cannabinoid administered over the multiple administrations is between one-sixth and one-half relative to the total administered dose of the at least one cannabinoid in unbound form for achieving the same degree of therapeutic effect.
23. The method according to claim 19, wherein the at least one cannabinoid is one or a combination of two or more of the group consisting of: THCA, A9-THC, A8-THC, CBDA, CBD, CBN, CBG, THCV, CBGA, CBC, HU-210, WIN 55,212-2 and JWH133, and nabilone.
24. The method according to claim 19, wherein the plasma protein or portion thereof is selected from the group consisting of: an albumin, a lipoprotein, a glycoprotein, and α, β, and γ globulins, and mixtures of one or more thereof.
25. The method according to claim 19, wherein the subject suffers from reduced appetite, the at least one cannabinoid comprises A-9THC, and the at least one cannabinoid is administered at a dose of between about 3 mg/week Δ-9-THC and about 9 mg/week Δ-9 THC.
26. The method according to claim 19, wherein the subject suffers from nausea, the at least one cannabinoid comprises A-9THC, and the at least one cannabinoid is administered at a dose of between about 12 mg/week Δ-9-THC and about 35 mg/week Δ-9 THC.
27. The method according to claim 19, wherein the subject suffers from pain associated with fibromyalgia, the at least one cannabinoid comprises nabilone, and the at least one cannabinoid is administered at a dose of between about 2 mg/week nabilone and about 7 mg/week nabilone.
28. The method according to claim 19, wherein the subject suffers from chronic pain, the at least one cannabinoid comprises nabilone, and the at least one cannabinoid is administered at a dose of between about 0.6 mg/week nabilone and about 1.75 mg/week nabilone.
WO 2018/167795
PCT/IL2018/050307
29. The method according to claim 28, wherein the chronic pain is associated with one or more of fibromyalgia, upper motor neuron syndrome, and central pain syndrome.
30. The method according to claim 19, wherein the subject suffers from chronic pain associated with cancer, the at least one cannabinoid conhaimprises THC, and the at least one cannabinoid is administered at a dose of between about 6 mg/week THC and about 17.5 mg/week THC.
31. The method according to claim 19, wherein the subject suffers from epilepsy, the at least one cannabinoid comprises CBD, and the at least one cannabinoid is administered at a dose of between about 233 mg/week CBD and about 700 mg/week CBD.
32. The method according to claim 19, wherein the subject suffers from epilepsy, the at least one cannabinoid comprises CBD, and the at least one cannabinoid is administered at a dose of between about 5.5 mg/kg/week CBD and about 17.5 mg/kg/week CBD.
33. The method according to claim 19, wherein the subject suffers from epilepsy associated with Dravet Syndrome or Lennox-Gastaut Syndrome, the at least one cannabinoid comprises CBD, and the at least one cannabinoid is administered at a dose of between about 23 mg/kg/week CBD and about 70 mg/kg/week CBD.
34. The method according to claim 19, wherein the subject suffers from epilepsy, the at least one cannabinoid comprises CBD and THC, and the at least one cannabinoid is administered at a dose of between about 3.2 mg/week THC with about 2.9 mg/week CBD and about 9.5 mg/week THC with about 8.7 mg/week CBD.
35. The method according to claim 19, wherein the subject suffers from chronic pain, the at least one cannabinoid comprises CBD and THC, and the at least one cannabinoid is administered at a dose of between about 3.2 mg/week THC with about 2.9 mg/week CBD and about 9.5 mg/week THC with about 8.7 mg/week CBD.
36. The method according the claim 35, wherein the chronic pain is associated with one or more of a nerve lesion, rheumatoid arthritis, a cancer, and multiple sclerosis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762472329P | 2017-03-16 | 2017-03-16 | |
US62/472,329 | 2017-03-16 | ||
PCT/IL2018/050307 WO2018167795A1 (en) | 2017-03-16 | 2018-03-16 | Cannabinoid formulations and dosage |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2018235442A1 true AU2018235442A1 (en) | 2019-10-31 |
Family
ID=63521893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018235442A Abandoned AU2018235442A1 (en) | 2017-03-16 | 2018-03-16 | Cannabinoid formulations and dosage |
Country Status (12)
Country | Link |
---|---|
US (2) | US20210121416A1 (en) |
EP (1) | EP3595693B1 (en) |
JP (1) | JP2020510077A (en) |
KR (1) | KR102621425B1 (en) |
CN (1) | CN110603047A (en) |
AU (1) | AU2018235442A1 (en) |
CA (1) | CA3056556A1 (en) |
ES (1) | ES2908141T3 (en) |
IL (1) | IL269305B1 (en) |
PL (1) | PL3595693T3 (en) |
RU (1) | RU2019131818A (en) |
WO (1) | WO2018167795A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115175675A (en) * | 2019-08-29 | 2022-10-11 | 伊祖恩制药公司 | Protein-based cannabis compositions |
CN116157137A (en) * | 2020-08-03 | 2023-05-23 | 塞斯帕克有限公司 | Method for maintaining microvascular integrity |
JP2023544355A (en) | 2020-10-01 | 2023-10-23 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | Protein-bound cannabinoid preparations and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04208280A (en) * | 1990-11-30 | 1992-07-29 | Matsushita Electric Ind Co Ltd | Cannabinol derivative, its production and cannabinol-protein conjugate |
GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
GB0202385D0 (en) * | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
KR102387044B1 (en) * | 2014-03-18 | 2022-04-14 | 이준 파마슈티컬스 코퍼레이션 | Protein-bound cannabinoid compositions |
-
2018
- 2018-03-16 AU AU2018235442A patent/AU2018235442A1/en not_active Abandoned
- 2018-03-16 JP JP2019550824A patent/JP2020510077A/en active Pending
- 2018-03-16 US US16/494,320 patent/US20210121416A1/en not_active Abandoned
- 2018-03-16 EP EP18767525.1A patent/EP3595693B1/en active Active
- 2018-03-16 CA CA3056556A patent/CA3056556A1/en active Pending
- 2018-03-16 ES ES18767525T patent/ES2908141T3/en active Active
- 2018-03-16 WO PCT/IL2018/050307 patent/WO2018167795A1/en unknown
- 2018-03-16 KR KR1020197029757A patent/KR102621425B1/en active IP Right Grant
- 2018-03-16 RU RU2019131818A patent/RU2019131818A/en not_active Application Discontinuation
- 2018-03-16 PL PL18767525T patent/PL3595693T3/en unknown
- 2018-03-16 CN CN201880030021.4A patent/CN110603047A/en active Pending
-
2019
- 2019-09-12 IL IL269305A patent/IL269305B1/en unknown
-
2023
- 2023-04-24 US US18/305,418 patent/US20230255902A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110603047A (en) | 2019-12-20 |
US20230255902A1 (en) | 2023-08-17 |
EP3595693A1 (en) | 2020-01-22 |
JP2020510077A (en) | 2020-04-02 |
EP3595693B1 (en) | 2021-12-15 |
RU2019131818A (en) | 2021-04-16 |
CA3056556A1 (en) | 2018-09-20 |
BR112019019245A2 (en) | 2020-04-14 |
ES2908141T3 (en) | 2022-04-27 |
KR20190126128A (en) | 2019-11-08 |
IL269305B1 (en) | 2024-07-01 |
US20210121416A1 (en) | 2021-04-29 |
KR102621425B1 (en) | 2024-01-05 |
PL3595693T3 (en) | 2022-03-28 |
WO2018167795A1 (en) | 2018-09-20 |
RU2019131818A3 (en) | 2021-07-09 |
IL269305A (en) | 2019-11-28 |
EP3595693A4 (en) | 2020-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230255902A1 (en) | Cannabinoid formulations and dosage | |
Jiang et al. | Anti-inflammatory effects of rosmarinic acid in lipopolysaccharide-induced mastitis in mice | |
Bian et al. | Dihydrolipoic acid protects against lipopolysaccharide-induced behavioral deficits and neuroinflammation via regulation of Nrf2/HO-1/NLRP3 signaling in rat | |
Zhan et al. | The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors | |
AU2012311483B2 (en) | Combination therapy using immunoglobulin and C1-inhibitor | |
Gao et al. | Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect | |
WO2006092741A2 (en) | Treatment of inflammatory disorders with praziquantel | |
US20210030678A1 (en) | Cannabinoid and cbd liposome formulations and uses thereof | |
RU2494736C2 (en) | Combination containing paclitaxel for treating ovarian cancer | |
WO2019159176A1 (en) | Compositions and methods for treatment of neurodegenerative diseases | |
JP2005537282A (en) | Inhibition of angiogenesis by cephalotaxin alkaloids, and derivatives, compositions and methods of use thereof | |
BR112019019245B1 (en) | CANNABINOID FORMULATIONS AND DOSAGE | |
Xiao et al. | Cathepsin S in the spinal microglia facilitates morphine-induced antinociceptive tolerance in rats | |
Singh et al. | Preclinical evidence-based neuroprotective potential of silibinin | |
JP2022519873A (en) | Cannabinoid receptor agonist and serine hydrolase enzyme inhibitor-based anti-anxiety therapeutic products | |
EP3079709A1 (en) | Ephedra alata extracts and methods of use thereof | |
US20230302026A1 (en) | Immunomodulation formulations and related methods | |
US20230405070A1 (en) | Plectranthus amboinicus extract for use in inhibiting immune responses | |
US20160296574A1 (en) | Ephedra alata extracts and methods of use thereof | |
Nwankwo et al. | Antimalarial potential of ethanol extract, and anti-inflammatory properties of flavonoid-, terpenoid-, and alkaloid-rich fractions of Sida linifolia L. | |
TW202406540A (en) | Method against snake envenomation | |
CN112843040A (en) | Application of ferulic acid derivative in preparation of medicine for treating ischemic stroke in convalescent period | |
CN110833551A (en) | Use of pyrazolopyrimidine derivatives for the treatment of acute pancreatitis | |
CA2996901A1 (en) | Composition for treating and preventing viral infections | |
htS Reserved | New Molecular Entities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |